Boehringer Ingelheim India Announces Partnership with Alivira Animal Health Limited

Business Wire India

Boehringer Ingelheim India Private Limited has entered into an agreement with Alivira Animal Health Limited (a fully owned subsidiary of Viyash Scientific Limited) for the distribution and promotion of its companion animal products portfolio in India. This partnership will leverage the growth opportunities in Indian pet healthcare market that is driven by increased pet ownership, awareness of preventive care and growing emphasis on animal well-being in India.

 

Boehringer Ingelheim India, said, “This partnership aligns with our long-term growth strategy for the animal health business in India and enables us to serve our customers with greater clarity, consistency, and care.  It positions us to scale efficiently while remaining focused on strategic leadership. Alivira Animal Health Limited will expand our sales capability across urban and rural India in the companion animal business, further enhancing market reach, access and driving execution excellence.”

 

He further adds, “Our portfolio continues to be built on high-quality products, supported by a robust and advancing pipeline, ensuring sustainable growth, strong governance, and consistent delivery for our customers. Together with Alivira Animal Health Limited, we can improve access, and responsiveness while preserving a clear strategy and brand experience to support the future growth of our companion animal business.”

 

Dr. Haribabu Bodepudi, MD & Group CEO - Viyash Scientific Limited, said, “This represents an important milestone in Viyash Scientific’s journey to become a key player in the companion animal segment. India offers tremendous opportunities for innovative medicines which cater to the medical needs of our pets. Driving access to high quality solutions for our pets in urban and rural India is at the heart of this partnership.  Alivira’s extensive geographical reach and on-ground capabilities, combined with Boehringer Ingelheim’s differentiated companion animal product portfolio strengthens our ability to serve veterinarians and pet parents across India effectively.”

(L-R) Rajaram Narayanan, CEO- Animal Health Viyash Scientific Limited, Meenal Gauri , GM and Head of Human Pharma, Boehringer Ingelheim India, Dr. Vinod Gopal, Head of Animal Health, Boehringer Ingelheim India

About Boehringer Ingelheim

 

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow.

 

Established in 2003, Boehringer Ingelheim India manages operations in India and neighbouring markets, offering innovative products in Human Pharma and Animal Health, with key therapy areas including diabetes, cardiovascular, and respiratory conditions. Learn more at https://www.boehringer-ingelheim.com/in

 

About Alivira Animal Health Limited

 

Alivira Animal Health Limited is a wholly owned subsidiary of Viyash Scientific Limited (formerly known as Sequent Scientific Limited). Headquartered in India, the company is among the top 25 Animal Health companies in the world. With over 3000 talented employees, Viyash Scientific Limited is an integrated pharmaceutical company having a rich portfolio of formulations and APIs for human and veterinary use, serving customers in over 100 countries. Viyash and its subsidiaries have manufacturing, R&D and distribution operations across India, Spain, Brazil, Turkey and USA, with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc.

 

Pursuant to approvals from the Registrar of Companies, SeQuent Scientific Limited has been officially renamed as Viyash Scientific Limited with effect from January 8, 2026, marking the completion of the merger between Sequent Scientific Limited and Viyash Life Sciences Private Limited.